JPRN-jRCT2080224729招募中1 期
A PHASE I STUDY OF ERY974 AS A SINGLE AGENT IN PATIENTS WITH GPC3-POSITIVE ADVANCED SOLID TUMORS
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 39
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Aged >18 years at time of informed consent
- •Eastern Cooperative Oncology Group(ECOG) Peformance Status(PS) of 0 or 1
- •Life expectancy >12 weeks from date of enrollment
- •Histologically or cytologically documented solid tumor
- •Advanced or recurrent cancer for which standard therapy is ineffective or inappropriate, or for which no standard therapy exists
- •Documented GPC3 positivity
排除标准
- •- Concurrent or prior autoimmune disease
- •- Uncontrolled diabetes mellitus
- •- Advanced/recurrent hepatocellular carcinoma
- •- Concurrent New York Heart Association (NYHA) Class >II congestive heart failure, myocardial infarction, arrhythmia, or unstable angina, or a history thereof within 6 months before enrollment
- •- Concurrent symptomatic cerebrovascular disorder or a history thereof within 6 months before enrollment
研究者
相似试验
进行中（未招募）
不适用
PHASE 2 STUDY OF SINGLE-AGENT PF 03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORSEUCTR2014-002286-30-HUPfizer Inc., 235 East 42nd Street, New York, NY 1001748
进行中（未招募）
1 期
PHASE 2 STUDY OF SINGLE-AGENT PF 03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORSADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORSMedDRA version: 18.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002286-30-BEPfizer Inc., 235 East 42nd Street, New York, NY 1001730
进行中（未招募）
不适用
PHASE 2 STUDY OF SINGLE-AGENT PF 03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORSADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORSMedDRA version: 18.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002286-30-GBPfizer Inc., 235 East 42nd Street, New York, NY 1001730
进行中（未招募）
不适用
PHASE 2 STUDY OF SINGLE-AGENT PF 03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORSADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORSMedDRA version: 18.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002286-30-DEPfizer Inc., 235 East 42nd Street, New York, NY 1001748
进行中（未招募）
1 期
PHASE 2 STUDY OF SINGLE-AGENT PF 03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORSADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORSMedDRA version: 17.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002286-30-ESPfizer Inc., 235 East 42nd Street, New York, NY 1001719